Pharma BD Deal Intelligence
Organon deepened Schering-Plough's pipeline but the financial and strategic strain helped make Schering itself a takeover target — Merck absorbed the whole company just two years later
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Schering-Plough Corp will buy Organon BioSciences, the drug unit of Netherlands-based Akzo Nobel, for $14.4 billion, giving the U.S. drugmaker an array of…
FTC challenged the acquisition over overlap in animal health (poultry vaccines) and required divestitures, but cleared the broader human pharmaceutical deal.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
EUR 11B / $14.5B cash. Closed Nov 2007. Human + animal health. Source: CNBC, Fierce Biotech, AkzoNobel press release.
Organon deepened Schering-Plough's pipeline but the financial and strategic strain helped make Schering itself a takeover target — Merck absorbed the whole company just two years later
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Schering-Plough Corp. / Organon BioSciences N.V. (Akzo Nobel) (this deal) | 2007 | $14.5B | 48 |
| Schering-Plough Corp. / Organon International | 2007 | $14.4B | 56 |
| Schering-Plough Corp. / Organon & Co. | 2007 | $14.4B | 48 |
| Schering-Plough Corp. / NeoGenesis Pharmaceuticals | 2005 | — | 30 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Becton, Dickinson and Company / C.R. Bard Inc. | 2017 | $24.0B | 77 |
← Browse all deals · How we score deals
More: 2007 deals · Schering-Plough Corp. deals · Multiple (undisclosed) deals